UnitedHealth Group Stock Performance
UnitedHealth Group shares closed at $396.30, reflecting a daily decline of approximately 1.02% per SID market data. The stock has underperformed over the near term, falling 6.03% over the past month, though it has recovered modestly over the trailing three months with a 2.51% gain. On a one-year basis, UNH has appreciated 16.77%, underscoring longer-term resilience despite recent selling pressure. The stock currently trades below its 50-day moving average of $412.60 but remains well above its 200-day moving average of $343.11, according to SID market data. The 14-day RSI sits at 39.6, approaching oversold territory and signaling sustained bearish momentum in recent sessions. UNH carries a beta of 0.432, indicating significantly lower volatility relative to the broader market. Average daily trading volume stands at approximately 8.77 million shares, reflecting robust institutional liquidity in the name.
UnitedHealth Group Valuation Analysis
UnitedHealth Group carries a market capitalization of approximately $305 billion and trades at a price-to-earnings ratio of 17.38, according to SID market data. This valuation sits below the broader S&P 500 average, suggesting the stock is priced at a discount relative to the general market despite its dominant position in the managed care industry. The price-to-book ratio stands at 3.19, per SEC filings, reflecting the company's substantial intangible assets and goodwill accumulated through acquisitions. The PEG ratio registers at negative 1.02, driven by negative forward earnings growth estimates that reflect near-term headwinds facing the healthcare sector. UNH currently offers a dividend yield of approximately 2.59%, providing meaningful income for shareholders. Within the healthcare sector, UnitedHealth's valuation metrics suggest the market is pricing in execution risk around regulatory and cost pressures while acknowledging the company's scale advantages and diversified revenue streams.
Smart Money Activity for UNH
UnitedHealth Group's composite smart money score stands at 59 out of 100, reflecting a neutral overall signal per SID market data. Institutional ownership conviction scores a perfect 25 out of 25, indicating broad and deep commitment from large fund managers. Congressional trading activity also registers exceptionally high at 24.2 out of 25, suggesting significant interest from lawmakers disclosed in recent filings. Insider activity presents a notably bullish skew, with 17 insider purchases versus only 3 sales across 20 total transactions in the last 90 days, according to SEC Form 4 filings. Despite scoring 0 out of 25 on the aggregate insider metric, the raw transaction data reveals a buy-to-sell ratio exceeding 5-to-1, which may indicate internal confidence in the company's forward trajectory. Dark pool activity scores 9.4 out of 25, suggesting moderate but not outsized off-exchange institutional positioning. The divergence between strong congressional and institutional signals and the muted insider composite score warrants continued monitoring.
UnitedHealth Group Earnings Outlook
UnitedHealth Group has demonstrated a consistent pattern of exceeding analyst expectations across its recent quarterly results. In the most recent reported quarter, the company posted earnings per share of $6.38 against a consensus estimate of $4.85, representing a positive surprise of $1.53, according to company earnings reports. The prior quarter similarly delivered an upside surprise, with actual EPS of $7.23 versus estimates of $6.56, a beat of $0.67. The earliest reported quarter showed EPS of $2.11 against a $2.10 estimate, a marginal beat of $0.01. Looking ahead, analysts project EPS of $6.81 for the upcoming quarter per consensus estimates. The cumulative surprise trend across three consecutive quarters of beats suggests management has maintained disciplined guidance practices. The magnitude of the most recent beat — over 31% above consensus — is particularly notable and may prompt upward revisions to forward estimates.
Wall Street Analyst Ratings for UNH
Wall Street consensus on UnitedHealth Group remains uniformly bullish, with all five most recent analyst actions reaffirming positive ratings per SID consensus data. On July 21, 2026, both Mizuho and JP Morgan maintained their Outperform and Overweight ratings respectively, following the company's latest earnings report. Barclays reiterated its Overweight rating on July 20, while RBC Capital and UBS both reaffirmed Outperform and Buy ratings on July 17, according to Wall Street analyst reports. Notably, none of the recent analyst updates involved downgrades or rating changes, with each firm maintaining its prior positive stance. This unanimous bullish positioning across five major institutions — spanning both U.S. and European brokerages — reflects broad confidence in UnitedHealth's fundamental outlook despite the stock's recent 6.03% monthly decline. The clustering of reaffirmations around mid-July 2026 aligns with post-earnings analyst updates, suggesting the strong quarterly beat reinforced existing investment theses across the Street.
